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Introduction: Bone marrow-derived stromal cells (BMSCs), also known as mesenchymal stem cells, are the focus of
intensive efforts worldwide to elucidate their function and biology. Despite the importance of BMSC migration for
their potential therapeutic uses, the mechanisms and signalling governing stem cell migration are still not fully
elucidated.
Methods: We investigated and detailed the effects of MCP-1 activation on BMSCs by using inhibitors of G
protein-coupled receptor alpha beta (GPCR αβ), ROCK (Rho-associated, coiled-coil containing protein kinase), and
PI3 kinase (PI3K). The effects of MCP-1 stimulation on intracellular signalling cascades were characterised by using
immunoblotting and immunofluorescence. The effectors of MCP-1-mediated migration were investigated by
using migration assays (both two-dimensional and three-dimensional) in combination with inhibitors.
Results: We established the kinetics of the MCP-1-activated signalling cascade and show that this cascade
correlates with cell surface re-localisation of chemokine (C motif) receptor 2 (CCR2) (the MCP-1 receptor) to
the cell periphery following MCP-1 stimulation. We show that MCP-1-initiated signalling is dependent on the
activation of βγ subunits from the GPCR αβγ complex. In addition, we characterise a novel role for PI3Kγ
signalling for the activation of both PAK and ERK following MCP-1 stimulation. We present evidence that the
Gβγ complex is responsible for PI3K/Akt, PAK, and ERK signalling induced by MCP-1 in BMSCs. Importantly, we
found that, in BMSCs, inhibition of ROCK significantly inhibits MCP-1-induced chemotactic migration, in
contrast to previous reports in other systems.
Conclusions: Our results indicate differential chemotactic signalling in mouse BMSCs, which has important
implications for the translation of in vivo mouse model findings into human trials. We identified novel components
and interactions activated by MCP-1-mediated signalling, which are important for stem cell migration. This work has
identified additional potential therapeutic targets that could be manipulated to improve BMSC delivery and homing.Introduction
Bone marrow-derived stromal cells (BMSCs), also known
as mesenchymal stem cells (MSCs), have generated much
interest in recent years. Critical properties that contribute
to the tissue regenerative capacity of BMSCs include their* Correspondence: frank.barry@nuigalway.ie
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to secrete paracrine factors, and their migratory capacity,
which is central to their ability to contribute to a repair
response [1–3]. However, the cellular mechanics and
chemotactic signalling events that guide BMSCs to their
appropriate microenvironments have not been fully eluci-
dated. Fully understanding these mechanisms will advance
the therapeutic utility of BMSCs, improving methods
for systemic delivery by enhancing efficiency of hom-
ing to target tissues. Although it has been previously
reported that human BMSCs migrate in response to
the chemokine, monocyte chemoattractant protein 1is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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completely elucidated. Furthermore, it was shown that
MCP-1 migration is mediated by chemokine (C motif) re-
ceptor 2 (CCR2) and the adapter molecule Pericentrin-1
(Nup85, FROUNT) [6, 7]. However, the kinetics of CCR2
activation and the downstream pathways involved remain
unclear.
Chemotaxis is initiated when chemokines bind to
transmembrane receptors, leading to the release of the
Gα and Gβγ subunits from the Gαβγ complex of G
protein-coupled receptors (GPCRs) [8, 9]. The selective
activation of distinct pathways suggests that the GPCRs
bind G proteins and additional effectors. Previously, it
was demonstrated that Pericentrin-1 binds activated
CCR2, linking it to the PI3 kinase (PI3K)-Rac-lamelli-
podium cascade [7]. However, it is unresolved whether
these signalling events are likewise involved in the
chemotactic response of BMSCs. Additionally, RhoGT-
Pase family members and the Rho kinase ROCK (Rho-
associated, coiled-coil containing protein kinase), which
are important mediators of polarisation and migration
in many cells types, remain to be confirmed in BMSCs
[10–15]. Here, we evaluate the role of ROCK, GPCR,
and PI3K signalling events which mediate the chemo-
tactic migration of BMSCs. Using a combination of
migration assays, high-resolution imaging, and pharma-
cological inhibitors, we have explored the critical medi-




BMSCs were isolated from 8- to 10-week-old BalbC mice.
Marrow was flushed from femurs and tibiae and plated
directly onto plastic. BalbC BMSCs were maintained in
modified Eagle’s medium-α (MEM-α) GlutaMAX™ (Life
Technologies, Carlsbad, CA, USA) supplemented with 10
% fetal bovine serum (HyClone, part of GE Healthcare,
Little Chalfont, UK), 10 % equine serum (HyClone), 1 %
L-glutamine, and 1 % penicillin-streptomycin. Cells were
seeded at a density of 5.7×103 cells/cm2, and all experi-
ments were performed by using BMSCs at passages 4–8.
Human MSCs were aspirated under sterile conditions
from the iliac crests of healthy human volunteers. The
obtained marrow was filtered with a 70-μm cell strainer
(Falcon, part of Thermo Fisher Scientific, Waltham, MA,
USA) before centrifuging at 400×g for 10 min. Cell pellets
were resuspended in media consisting of MEM-α (Gibco,
part of Invitrogen, Carlsbad, CA, USA), supplemented
with 10 % fetal bovine serum (Gibco) and 1 % antibiotics
(streptomycin and penicillin) (Gibco), and cultured in
175-cm2 flasks at 37 °C in a humidified atmosphere con-
taining 5 % CO2. At day 4, the cultures were washed with
phosphate-buffered saline to remove the non-adherentcells and further expanded until more than 80 % conflu-
ence, when they were harvested and expanded in 175-cm2
flasks. After subculture, these cells were designated as pas-
sage 1.
BMSCs were characterised by their ability to differenti-
ate into chondrocytes, adipocytes, and osteoblasts and
were confirmed to be CD105-, CD73-, Sca1-, CD29-,
CD44-positive and CD34-, CD45-, and CD31-negative,
as previously described [16]. BMSCs were cultured in
serum-free conditions for 2 h prior to pre-treatment with
either the CCR2 antagonist: 10 μM RS102895 (Sigma-
Aldrich, St. Louis, MO, USA), 10 μM Anti-BetaGamma
(MPS-Phosducin-like protein C terminus) (AnaSpec,
Fremont, CA, USA) or the PI3K inhibitor: 5 μM LY294002
(Merck, Kenilworth, NJ, USA). For two-dimensional (2D)
migration assays, BMSCs were cultured in serum-free con-
ditions overnight prior to assays. BMSCs were pre-treated
with ROCK inhibitor (10 μM Y27632; Sigma-Aldrich) in
combination with serum-free conditions for 24 h.
All work (both human and animal related) was ap-
proved by the Animal Ethics Committee, National
University of Ireland, Galway, and conducted under li-
cense from the Department of Health, Ireland. Human
MSCs were obtained and purified in accordance with the
described protocol (above) from fully informed and con-
senting patients as approved by the Animal Ethics Com-
mittee, National University of Ireland, Galway. All animal
experiments were conducted in compliance with the
“Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research and the “Guidelines
for the Care and Use of Laboratory Animals” prepared by
the National Academy of Science, which was published by
the National Institutes of Health (ISBN 0-309-05377-3,
revised 1996).
Migration assays
Three-dimensional (3D) migration in response to MCP-
1 (R&D Systems, Minneapolis, MN, USA) through a
porous membrane (8-μm pore size) was assessed using
the xCELLigence Real Time Cell Analyzer (Roche Ap-
plied Science, Basel, Switzerland). The xCELLigence sys-
tem measures electrical impedance across a high-density
electrode array coating the bottom of a well. The imped-
ance values are converted into a migration index (MI)
and these values directly correspond to the number of
adhered cells [17]. When cells are not present or are not
adhered to the electrodes, the MI is 0. Optimisation in-
dicating the linear phase of BMSC migration occurred
within 3 h (data not shown), and subsequently all BMSC
migration was recorded in real time for 3 h. For 3D mi-
gration, MSCs were cultured in serum-free conditions
for 4 h prior to all assays. Assays with combinations of
the indicated inhibitors were performed for an additional
2 h. BALB/c BMSCs (5×104) suspended in serum-free
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Invasion and Migration plate, and recombinant mouse
MCP-1 in serum-free medium was added to the lower
wells. Lower wells containing either 0 % (negative) or
10 % (positive) serum were included as controls. 2D mi-
gration was assessed by using the μslide chemotaxis2D
system (ibidi, Martinsried, Germany) in the presence of
a stable linear chemoattractant gradient established
over 3 h in accordance with the instructions of the
manufacturer. Cells from the 2D migration were visual-
ized as indicated below.
Immunofluorescence
BMSCs were seeded onto glass slides and cultured for
48 or 24 (2D chemoattraction assays) h prior to the indi-
cated treatments. BMSCs were exposed to 20 ng/ml
MCP-1 at 37 °C for the indicated times and fixed in 4 %
paraformaldehyde. Cells were permeabilised with 0.1 %
TritonX100 for 30 min, unless otherwise indicated. Fixed
cells were blocked with 5 % BSA (Sigma-Aldrich) and
stained with the following antibodies: anti-CCR2 antibody
([E68] ab32144; Abcam, Cambridge, UK), antiPericentrin-
1 antibody (Santa Cruz Biotechnology, Dallas, TX, USA),
or mouse monoclonal anti αtubulin (T5168; Sigma-
Aldrich). Bound antibodies were detected by using the
appropriate secondary antibody: Cy3-labeled anti-rabbit
antibody (Jackson ImmunoResearch Europe, Newmarket,
Suffolk, UK), FITC labeled anti-goat IgG antibody (Santa
Cruz Biotechnology), or Dylight 488labeled anti-mouse
antibody. F-Actin was detected by using Rhodamine-
conjugated phalloidin (Sigma-Aldrich). Isotype controls
were mouse and rabbit (Thermo Fisher Scientific). Slides
were mounted with slowfade gold antifade reagent with
4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen). Z-
stack images were captured by using an Andor Revolution
spinning disk confocal microscope (Andor, Belfast, North-
ern Ireland, including an Olympus inverted IX 81 micro-
scope, Olympus, Tokyo, Japan, 40× or 60× oil immersion
objective lenses with an Andor iXonEM+ EMCCD camera).
Z-stack images were processed by using Andor IQ 2.3
software, and images were presented as maximum inten-
sity projections.
Immunoblotting
BMSCs were cultured for 48 h, serum-depleted, and
treated with the inhibitors as indicated. Whole cell ly-
sates were prepared by using RIPA buffer containing a
protease inhibitor cocktail (Roche, Basel, Switzerland)
with an additional 100 mM phenylmethylsulfonyl fluor-
ide (PMSF) and 100 mM NA3VO4 (Sigma-Aldrich).
Whole cell lysates were separated by SDS-PAGE, and
proteins were transferred to polyvinylidene difluoride
(PVDF) (Immobilon, EMD Millipore Corporation, Billerica,
MA, USA) membranes in accordance with the instructionsof the manufacturer. Membranes were blocked with 5 %
skim milk powder and incubated overnight at 4 °C with
the indicated primary antibodies: phosphoAktSer473
(Cell Signaling Technology, Beverly, MA, USA), AKT
(Cell Signaling Technology), phosphoERK1/2 (Cell Signal-
ing Technology), ERK (Cell Signaling Technology), phos-
phoPAK1Ser199/204/phosphoPAK2Ser192/197 (Cell Signaling
Technology), and PAK1/2/3 (Cell Signaling Technology).
Membranes were incubated for 1 h at room temperature
with a horseradish peroxidase-conjugated anti-mouse or
anti-rabbit IgG secondary antibody (Jackson ImmunoRe-
search Laboratories Inc., West Grove, PA, USA). Bound
antibodies were visualized by using SuperSignal West Pico
Chemiluminescent substrate Thermo Fisher Scientific
(Waltham, MA, USA), and the band intensities were
quantified by using AlphaView software (FluorChem sys-
tems; ProteinSimple, San Jose, CA, USA).
Viability and cytotoxicity assay
Effect of serum-free medium (SFM) treatment, alone or
in combination with the indicated inhibitors, on BMSC
viability and cytotoxicity was assayed by using the ApoTox-
Glo™ Triplex Assay (Promega Corporation, Madison, WI,
USA) in accordance with the instructions of the manufac-
turer, under the indicated conditions.
Statistical analysis
To avoid any bias, counts were recorded from multiple
fields from the indicated number of independent cell
culture preparations. Data analyses were performed by
using Prism 5 software (GraphPad Software, Inc., La
Jolla, CA, USA) or Microsoft Excel (Microsoft Corpor-
ation, Redmond, WA, USA). Statistical significance was
calculated with a one-way analysis of variance by using a
Kruskal-Wallis test with a post hoc Dunn’s or Tukey test
to evaluate the statistical significance between groups,
unless otherwise indicated. A P value of less than 0.05
(*) was deemed significant, P value of less than 0.01 (**)
very significant, and P value of less than 0.001 (***)
highly significant, as stated in the figure legends. Counts
of cell numbers represent at least three separate discrete
experiments with more than 100 counts made for each
separate independent experiment (n and minimum
number measurements for each separate experiment are
indicated in figure legends).
Results
BMSCs migrate in response to the chemokine MCP-1
We found that our cultured mouse BMSCs displayed
three distinct populations: a tiny immotile fraction (<1 %),
polarised BMSCs (~30 %) characterised by an accumula-
tion of actin filaments at the leading edge of the cell, and
actively motile BMSCs (~10 %) characterised by defined
lamellipodia (concentrated F-actin staining at the cell
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actin-positive cell extension (Additional file 1: Figure S1).
The remaining cells observed were characterised as non-
polarised, non-migrating. As previously demonstrated
[5, 18], MCP-1 induced significant migration (Fig. 1a and
Additional file 2: Figure S2a) and polarisation (demon-
strated by F-actin re-localisation) in serum-starved mouse
BMSCs (Fig. 1b). In addition, a trend (non-significant) of
MCP-1 inducing greater migration than the non-specific
chemoattractant fetal calf serum (FCS) was observed.
Interestingly, investigating the dose-dependent effects of
MCP-1 exposure on migration, we found that 20 and 50
ng/ml MCP-1 induced significant migration, comparedFig. 1 BMSCs migrate and polarise in response to MCP-1. a Serum-starved
two-dimensional system; 24-h pre-treatment with SFM and migration followin
three independent experiments (>100 cells evaluated for each separate indep
mean. A P value of less than 0.05 (*) was deemed significant, and a P value of
polarise in response to MCP-1 treatment. BMSCs immunofluorescently stained
and 10 % FCS and 20 ng/ml MCP-1 treatment for 3 h. DNA stained with DAP
4',6-diamidino-2-phenylindole, FCS fetal calf serum, MCP-1 monocyte chemoawith the non-specific chemoattractant fetal bovine serum
or higher doses of MCP-1 (Additional file 2: Figure S2b).
Subsequently, 20 ng/ml MCP-1 was used for all experi-
ments. Supporting previous work demonstrating ex-
pression of the MCP-1 receptor gene CCR2 [6, 19],
MCP-1 induced significant migration in human BMSCs
(Additional file 3: Figure S3a, b). However, in contrast
to mouse BMSCs, no difference between FCS- and
MCP-1-mediated migration in human BMSCs was ob-
served. Although ROCK inhibitor Y27632 did not in-
hibit human BMSC MCP-1-mediated migration, it did
induce stellate morphology, indicating its effectiveness
(Additional file 3: Figure S3a).BMSC migration in response to a gradient of 0–20 ng/ml MCP-1 in a
g 3-h exposure to 20 ng/ml MCP-1. SFM was set to 1. Graph represents
endent experiment). Data are presented as mean ± standard error of the
less than 0.001 (***) highly significant. b Serum-starved migrating BMSCs
with F-actin (red) and α-tubulin (green), following 24-h SFM treatment
I (blue). Scale bar = 10 μm. BMSC bone marrow-derived stromal cell, DAPI
ttractant protein 1, SFM serum-free medium
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in mouse BMSCs
So far, the effect of ROCK inhibition on chemotactic-
induced migration has not been examined in mouse
BMSCs. Consistent with previous reports, Y27632 pre-
treatment resulted in mouse BMSCs with a stellate
morphology (Additional file 4: Figure S4a), characteristic
of inhibited RhoA/ROCK signalling [20–22]. Further-
more, MCP-1 treatment of Y27632 pre-treated cells did
not affect this stellate morphology (Additional file 4:
Figure S4a). To investigate the effects on chemotactic
migration, BMSCs were cultured in the presence or ab-
sence of the ROCK inhibitor, Y27632, for 24 h prior to
exposure to an MCP-1 gradient in a 2D migration assay
(Fig. 2a and Additional file 4: Figure S4b). We found
that Y27632 pre-treatment of mouse BMSC resulted in
a significant inhibition in MCP-1-induced migration in
both a 3D (Fig. 2b) and 2D migration assay (Fig. 2c).
Significantly, however, pre-treatment of human BMSCs
with Y27632 did not inhibit MCP-1-mediated migration
in the 2D assay (Fig. 2d). Interestingly, human BMSCs
treated with Y27632 also displayed a stellate morph-
ology (Additional file 3: Figure S3a, b).MCP-1-dependent signalling in mouse BMSCs
As chemotactic migration in mouse BMSCs was inhib-
ited by Y27632 treatment, in contrast to previous mi-
gration studies [12, 14, 20, 23–25], we characterised
the MCP-1-dependent migration signalling pathway in
mouse BMSCs. Investigating localisation of the extra-
cellular MCP-1 receptor CCR2 (a member of the G
protein-coupled receptor superfamily) on the surface
of non-permeabilised untreated mouse BMSCs, we
found that CCR2 displayed diffuse generalised cell sur-
face staining (Fig. 3a). To support previous studies, we
carried out a more detailed analysis, characterising the
kinetics of this re-localisation. After 2 min of MCP-1
treatment, surface CCR2 re-distributed to the cell
periphery and displayed a distinct punctate staining
pattern (Fig. 3a, white arrows). Confirming a re-distribution
of CCR2, we demonstrated no change in CCR2 levels fol-
lowing MCP-1 treatment at the indicted time points
(Fig. 3b).
To further examine MCP-1-dependent signalling, the
CCR2 adaptor Pericentrin-1 (Nup85, FROUNT) [7] was
investigated. After MCP-1 treatment, Pericentrin-1 was
observed re-localising to the cell periphery (Fig. 3c). In
addition, after 10 min of MCP-1 treatment, CCR2 staining
in permeabilised BMSCs displayed peri-nuclear staining,
as previously reported [6, 7] (Fig. 3c). Investigating the
kinetics of Pericentrin-1 re-localisation, we found that this
occurred swiftly, between 5 and 10 min after MCP-1 treat-
ment (Fig. 3c).MCP-1 signals migration through Pericentrin-1 and the
βγ complex
To determine whether MCP-1 signalling required CCR2
activity, the CCR2 inhibitor (RS102895) [26] was employed.
Inhibition of CCR2 activity abrogated the MCP-1-mediated
re-localisation of CCR2 and Pericentrin-1 (Fig. 3d). This in
turn led to a significant inhibition of MCP-1-mediated
migration (Fig. 3e and Additional file 5: Figure S5a). To
further probe the MCP-1-mediated signalling cascade, the
role of GPCRs was investigated by using the cell-permeable
peptide MPS-Phos, which sequesters the βγ complex [27].
Pre-treating mouse BMSCs with MPS-Phos abolished
MCP-1-dependent redistribution of both CCR2 and
Pericentrin-1 (Fig. 3f). Consistent with CCR2 inhibition,
pre-treatment with more than 5 μM MPS-Phos resulted in
significant inhibition of MCP-1-mediated migration (Fig. 3g
and Additional file 5: Figure S5b).MCP-1-dependent PI3Kγ signalling
To determine whether MCP-1-mediated migration re-
quired signalling though PI3K in mouse BMSCs, phos-
phorylation of the PI3K target AKT was examined. After
MCP-1 treatment, a time-dependent increase in PI3K-
dependent AktSer473 phosphorylation was observed (Fig. 4a, b).
Quantification revealed that MCP-1 treatment induced a
two-fold increase in phosphorylated AktSer473 (pAktSer473)
(Fig. 4c, where phosphorylated AktSer473 levels following 24 h
SFM media set to 1). Furthermore, combining RS102895
pre-treatment and MCP-1 resulted in a marked decrease in
pAktSer473. Interestingly, pre-treatment with MPS-Phos before
MCP-1 treatment did not significantly effect pAktSer473 levels,
indicating that the βγ complex signals though an alternate
pathway following MCP-1 treatment. To further dissect this
signalling cascade, we employed the PI3K inhibitor, LY294002.
Mouse BMSCs pre-treated with LY294002 had no MCP-1-
induced phosphorylation of AktSer473 and indeed had pAkt-
Ser473 levels that were barely detectable (Fig. 4b, c). This
reduction in pAktSer473 led to a de-sensitization of BMSCs to
the effects of MCP-1, resulting in a significant inhibition of
MCP-1-induced migration (Fig. 4c and Additional file 5:
Figure S5c).The MCP-1 signalling cascade requires ERK1
phosphorylation to induce migration
To determine whether GPCR βγ mediated ERK activa-
tion required for MCP-1-mediated signalling in our
model system, we treated mouse BMSCs with MCP-1
and evaluated the activation of PAK1 and PAK2, which
are upstream of ERK activation. We found that SFM-
treated cells exposed to MCP-1 displayed activation of
PAK1 and PAK2 (through phosphorylation of PAK1 at
Ser199/204 and PAK2 at Ser192/197) as swiftly as 2 min
(Fig. 5a, b, left).
Fig. 2 ROCK inhibition significantly decreases BMSC polarisation and migration. a ROCK inhibition (10 μM Y27632 pre-treatment for 3 h) significantly
reduces serum-starved BMSC polarisation in response to an MCP-1 gradient in a 2D model. Permeabilised serum-starved BMSCs immunofluorescently
stained with F-actin (red) and α-tubulin (green) and DNA stained with DAPI (blue), following the indicated treatments. Scale bar = 10 μm. b, c ROCK
inhibition (10 μM Y27632 combined with SFM for 24 h) significantly reduces MCP-1-stimulated BMSC migration. b ROCK inhibition (10 μM Y27632
combined with SFM for 24 h) significantly reduces BMSC migration in a three-dimensional assay in response to MCP-1. Graph represents three separate
independent experiments. Data are presented as mean ± standard deviation. The migration index (MI) is a relative change in measured electrical
impedance. When there are no cells, MI is 0. Increasing MI is a quantitative measure of cells attached to the electrodes, representative of cell numbers
migrating though a membrane. c, d ROCK inhibition (10 μM Y27632 combined with SFM for 24 h) significantly reduces BMSC 2D migration in mouse
(c) but not human (d) cells in response to 3-h MCP-1 exposure. SFM set = 1. Graphs represent three independent experiments (>100 cells evaluated
for each separate independent experiment). Data are presented as mean ± standard error of the mean. A P value of less than 0.05 (*) was deemed
significant, and a P value of less than 0.001 (***) highly significant. 2D two-dimensional, BMSC bone marrow-derived stromal cell, DAPI 4',6-diamidino-2-
phenylindole, MCP-1 monocyte chemoattractant protein 1, ROCK Rho-associated, coiled-coil containing protein kinase, SFM serum-free medium
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Fig. 3 CCR2 and GPCR βγ activity is required for MCP-1-mediated migration. a Surface CCR2 re-localises after MCP-1 treatment. Immunofluorescent
staining of non-permeabilised serum-starved BMSCs, following the indicated treatments at the indicated times. CCR2 (red). α-tubulin (green). DNA
stained with DAPI (blue). Scale bar = 10 μm. b Immunoblotting of BMSC whole cell lysates for CCR2 and β-actin following MCP-1 treatment; 100 μg of
total cell extract/lane. Representative blot of three separate independent experiments is shown. c Kinetics of Pericentrin-1 re-localisation after MCP-1
treatment. Immunofluorescent staining of permeabilised serum-starved BMSCs. CCR2 (red) and Pericentrin-1 (green). DNA stained with DAPI (blue).
Scale bar = 10 μm. d Serum-starved BMSCs pre-treated with 10 μM RS102895 (βγ GPCR subunit inhibitor) and stained after exposure to MCP-1. CCR2
(red). α-tubulin (green). DNA stained with DAPI (blue). Scale bar = 10 μm. e 24-h treatment with 10 μM RS102895 combined with serum starvation
inhibits MCP-1-mediated BMSC migration in 3D. Graph represents three separate independent experiments. Data are presented as mean ± SD.
f MCP-1-mediated Pericentrin-1 re-localisation is inhibited by 24-h pre-treatment with 10 μM MPS-Phos (GPCR βγ inhibitor) and SFM. Permeabilised
BMSCs stained with CCR2 (red) and α-tubulin (green). DNA stained with DAPI (blue). Scale bar = 10 μm. g Combination of serum-starved BMSCs with a
GPCR βγ inhibitor (10 μM MPS-Phos) for 24 h significantly reduced MCP-1-mediated migration in 3D. Graph represents three separate independent
experiments. Data are presented as mean ± SD. A P value of less than 0.05 (*) was deemed significant. 3D three dimensions, BMSC bone
marrow-derived stromal cell, CCR2 chemokine (C motif) receptor 2, DAPI 4′,6-diamidino-2-phenylindole, GPCR G protein-coupled receptor,
MCP-1 monocyte chemoattractant protein 1, MPS-Phos MPS-phosducin-like protein C terminus, SD standard deviation, SFM serum-free medium
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Fig. 4 MCP-1-induced migration is dependent on GPCR βγ subunit
and PI3K activity. a Kinetics of MCP-1-mediated AKT signalling.
Immunoblotting for phosphorylated AktSer473 and total Akt following
serum-starved BMSCs exposed to MCP-1 for the indicated times;
100 μg of total cell extract/lane. Representative blot of three separate
independent experiments is shown. b Dependence of the MCP-1
signalling cascade on CCR2 and PI3Kγ activity (inhibited by 24-h serum
starvation combined with 10 μM RS102895 and 10 μM LY294002,
respectively). Immunoblotting for pAktSer473 and total Akt. Whole
cell extracts prepared from serum-starved BMSCs pre-treated with
the indicated inhibitors (10 μM RS102895, GPCR βγ subunit inhibitor
10 μM MPS-Phos, or 5 μM PI3K inhibitor LY294002) for 24 h prior to
MCP-1 exposure for the indicated time; 100 μg of total cell extract/
lane. Representative blot of three separate independent experiments
is shown. c Densitometric quantification of b (AktSer473 phosphorylation).
Untreated serum-starved BMSC AktSer473 levels were set to 1. Graph
represents three separate independent experiments. Data are presented
as mean ± standard deviation. d PI3Kγ activity is required for MCP-1-
induced BMSC migration in three dimensions. PI3Kγ activity inhibited by
24-h pre-treatment with 5 μM LY294002. Graph represents three separate
independent experiments. Data are presented as mean ± standard
deviation. A P value of less than 0.05 (*) was deemed significant.
BMSC bone marrow-derived stromal cell, CCR2 chemokine (C motif)
receptor 2, GPCR G protein-coupled receptor, MCP-1 monocyte
chemoattractant protein 1, PI3K PI3 kinase, SFM serum-free medium
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effect on PAK1Ser199/204 and PAK2Ser192/197 phosphorylation
by combining the previously described inhibitors (RS102895,
MPS-Phos, LY294002, and Y27632; Figs. 2, 3, and 4) and
MCP-1 treatment (Fig. 5a, b, right side). We found that
PI3K (LY294002) and ROCK (Y27632) inhibition led to a
noticeable decrease in MCP-1-induced PAK2Ser192/197
phosphorylation (Fig. 5a). Following this trend, both CCR2
and GPCR βγ inhibition also reduced the MCP-1 induc-
tion of PAK2Ser192/197 phosphorylation, although quantifica-
tion revealed that this was not statistically significant
(Fig. 5b). Importantly, we found that 24-h SFM treatment
alone, or in combination with the inhibitors, did not
significantly affect BMSC viability or cytotoxicity or induce
apoptosis (Additional file 6: Figure S6).ERK and PAK activation is required for MCP-1 stimulated
migration
To further investigate the consequences of induced (acti-
vation of ) PAK1 and PAK2 signalling, we explored the
effects of MCP-1 treatment on the downstream mole-
cules extracellular signal-regulated protein kinases 1 and
2 (ERK1/2). BMSCs pre-treated with SFM were exposed
to MCP-1, and the kinetics of ERK1 and 2 phosphoryl-
ation (pERK1/2) were investigated (Fig. 5c). After 5 min
of MCP-1 treatment, there was a marked increase in
pERK1, which had almost entirely diminished by 30 min
after treatment (Fig. 5c, d, left side). Interestingly, pERK2
was also strongly increased at 2 min after MCP-1
Fig. 5 PAK and ERK activation in response to MCP-1 is dependent on GPCR βγ subunit, PI3Kγ, and ROCK activity. a Immunoblotting for phosphorylation
of PAK1Ser199/204 and PAK2Ser192/197 and total PAK1/2. Serum starvation of BMSCs in combination with 10 μM RS102895, 10 μM MPS-Phos, 5 μM
LY294002, or 10 μM Y27632 for 24 h and exposed to MCP-1 for the indicated times; 100 μg of total cell extract/lane. Representative blot of three separate
independent experiments is shown. b Densitometric quantification of a (PAK1Ser199/204 and PAK2Ser192/197 phosphorylation). Untreated serum-starved
BMSC PAK1Ser199/204 and PAK2Ser192/197 levels were set to 1. Graph represents three separate independent experiments. Data are presented as mean ±
standard deviation. c Immunoblotting for phosphorylation of ERK1/2 and total ERK1/2 following serum-starved BMSCS was pre-treated with MCP-1 for
the indicated times or with 10 μM RS102895, 10 μM MPS-Phos, 5 μM LY294002, or 10 μM Y27632 and exposed to MCP-1; 100 μg of total cell extract/lane.
Representative blot of three separate independent experiments is shown. d Densitometric quantification of c (ERK1/2 phosphorylation). Untreated serum-
starved BMSC pERK1/2 levels were set to 1. Data are presented as mean ± standard deviation. Graph represents three separate independent experiments.
BMSC bone marrow-derived stromal cell, ERK extracellular signal-regulated kinase, GPCR G protein-coupled receptor, MCP-1 monocyte chemoattractant
protein 1, MPS-Phos MPS-phosducin-like protein C terminus, PAK P21 protein (Cdc42/Rac)-activated kinase 1, PI3K PI3 kinase, ROCK Rho-associated,
coiled-coil containing protein kinase
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returned to control levels by 30 min after treatment.
To explore the role of MCP-1 stimulation on this signal-
ling cascade, we evaluated the effects of the previously
described inhibitors (RS102895, MPS-Phos, LY294002,
and Y27632; Figs. 2, 3, and 4) in combination with MCP-1
treatment. Accompanying the results of inhibition of
pPAK1/2, we observed a reduction in the levels of pERK1/
2 (Fig. 5c, d, right side). Supporting previous reports in
human cells [28, 29], Y27632 pre-treatment combined
with MCP-1 led to a decrease in pERK1/2. However,
there are conflicting reports indicating that Y27632 did
not affect phosphorylation of ERK1 and 2 in human
leukocytes [30].
Discussion
The ability of stem cells to migrate provides the basis for
the therapeutic treatment of a broad spectrum of condi-
tions via systemic infusion of ex vivo preparations of
stem cells. To maximize their therapeutic efficacy, an
understanding of the various molecular mechanisms and
signalling cascades mediating stem cell migration is
essential [8, 31]. Furthermore, characterising the differ-
ences in migration mechanisms between human and the
model organism mouse is essential to allow results from
in vivo models to be accurately and meaningfully trans-
lated into human trials.
Here, we have highlighted key differences in the way
mouse BMSCs respond and signal in response to the
key chemokine MCP-1 (Fig. 6). In addition, we have
revealed previously unknown insights into the timing
of these signalling cascades and characterised the key
players in the cascades that facilitate mouse BMSC mi-
gration in response to chemokines (Figs. 3, 4, and 5).
Interestingly, we found that chemotactic migration of
mouse BMSCs requires ROCK activity (Fig. 2), in con-
trast to reports in other organisms (human, chicken,
rat, and mouse) and cell types (glioma, mouse embry-
onic fibroblast, chick embryonic heart fibroblast,
MSCs, and breast cancer) [12, 14, 20, 23–25]. Intri-
guingly, our findings were supported by other studies
but only in human cells [10, 28, 30, 32, 33]. Signifi-
cantly, in response to MCP-1, ROCK-inhibited BMSCs
were unable to migrate in a 3D assay and their ability
to migrate in a 2D assay was also severely reduced
(Fig. 2b, c). Interestingly, we found that BMSCs dis-
played an MCP-1 dose-dependent inhibition of migra-
tion (Additional file 2: Figure S2b). This suggests the
presence of a positive feedback loop mechanism, where
lower concentrations of MCP-1 attract BMSCs and the
higher concentrations encountered at the site of MCP-
1 secretion result in a settling and retention of BMSCs.
Indeed, the MCP-1 gradient used in our study would
include the reported plasma levels of MCP-1 in healthyindividuals (0.1–0.7 ng/ml) [34–36]. Supporting this,
we found that the majority of migrating cells were
observed at the lower end of the MCP-1 gradient (data
not shown). It is possible that acute exposure to MCP-
1 alters the differentiation potential of BMSCs; how-
ever, owing to the extremely short time frames investi-
gated, additional experimentation would be required to
confirm this.
To investigate the signalling cascades involved in
mouse BMSC migration, we began with MCP-1 ligand
binding and receptor activation and tracked this signal-
ling, which ultimately results in cytoskeletal reorganisation
and migration. We found that this sequence of events,
including the clustering of Pericentrin-1, is entirely
dependent on the release and activation of the βγ
subunits from the Gαβγ receptor complex. This is
supported by our findings that βγ subunit activation is
required for BMSC migration in response to MCP-1.
Importantly, we demonstrate that the chemotactic mi-
gration cascade is initiated with CCR2 re-localisation,
supporting previous findings [37]. However, this activa-
tion does not affect expression, particularly in such
short time frames (Fig. 3).
Importantly, we defined the previously unknown kin-
etics of this signalling cascade, and using specific inhib-
itors we were able to characterise the key players in
mouse BMSC chemotactic migration (Figs. 3, 4, and 5).
We demonstrate that ROCK inhibition in BMSCs sig-
nificantly retards migration which is likely through the
observed disruption of ERK1/2 phosphorylation; how-
ever, this remains to be verified directly by ERK1/2 in-
hibition. This is a novel finding which is in contrast to
a previous report of ROCK inhibition which, while inhi-
biting chemotactic migration, did not affect ERK1/2
phosphorylation [30]. It is interesting to note that the
underlying signalling was different, which may repre-
sent a fundamental difference in the cell types (mouse
BMSCs versus human leukocytes), chemokine (fMLP
versus MCP-1) or receptor (FRP1 versus CCR2). Fur-
ther work will need to focus on different chemokines
that induce BMSC migration, such as transforming
growth factor-beta, and determine whether they share
common signalling pathways. Our work has highlighted
the importance of determining whether these pathways
are conserved in human BMSCs, which may impact on
any therapeutic applications.
We found that, in BMSCs, PI3Kγ plays a pivotal role
in chemotactic-induced signalling and migration, sup-
porting previous work in monocytes and macrophages
[9, 38]. Importantly, our data show that the transient
phosphorylation of ERK succeeds the transient phos-
phorylation of PAK (Fig. 5). This signalling is import-
ant for defining the leading edge of the cell in response to
a chemotactic signal, as PI3Ks contribute to cell polarity
Fig. 6 Proposed model of MCP-1-dependent signalling cascade in mouse BMSCs. Solid lines indicate direct interactions. Dotted lines indicate
indirect actions. BMSC bone marrow-derived stromal cell, ERK extracellular signal-regulated kinase, MCP-1 monocyte chemoattractant protein 1,
PAK P21 protein (Cdc42/Rac)-activated kinase 1, PI3K PI3 kinase, Rac Ras-related C3 botulinum toxin substrate 1, RhoA rhodopsin A, ROCK
Rho-associated, coiled-coil containing protein kinase
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Pase, Rac. Activated Rac (RacGTP) then interacts with
several downstream effectors, PAK being one of them,
to coordinate cytoskeletal reorganization, lamellipodia
formation, and resultant migration [39, 40]. Although
active Rac (through ERK and PAK) and associated
signalling is involved in orchestrating cytoskeletal dy-
namics at the leading edge of the cell, Rho/ROCK haslargely been implicated in retraction at the rear of mi-
grating cells [10, 30, 41, 42]. However, recent reports have
confirmed that Rho/ROCK signalling is also active in
lamellipodia [22, 43, 44].
Conclusions
Our findings advance our understanding of bone mar-
row stromal (mesenchymal stem) cell biology and the
Ryan et al. Stem Cell Research & Therapy  (2015) 6:136 Page 12 of 14mechanisms orchestrating chemotactic migration. Using
a systematic approach, we mapped additional compo-
nents to the chemokine signalling pathway and provide
additional novel data concerning the timing of these sig-
nals (Fig. 6). Furthermore, for the first time, our work
provides a detailed mechanistic analysis of motility
signalling in BMSCs. This is significant, as increasing
our knowledge of the chemokine-dependent signalling
mechanisms essential for migration is undeniably re-
quired to fully exploit any therapeutic applications. In
addition, we define and highlight key areas where the
model organism Mus musculus differs from humans,
which may affect the translation of therapeutic applica-
tions. Finally, we have described potential additional
therapeutic targets in BMSCs that could be exploited to
improve delivery, homing, and retention of BMSCs to
sites of injury or disease.Additional files
Additional file 1: Figure S1. Stages of BMSCs observed in culture.
Permeabilised serum-starved BMSCs immunofluorescently stained with
F-actin (red) and α-tubulin (green) and DNA counter-stained with DAPI
(blue). Scale bar = 10 μm. Representative BMSC stages observed are
immotile, polarised, and actively motile. F-Actin filaments accumulate at
the leading edge in polarised BMSCs. Actively motile BMSCs display an
accumulation of F-Actin and α-tubulin at the cell edge orientated in the
direction of movement. Isotype controls, mouse and rabbit (Thermo
Fisher Scientific), demonstrate specificity of staining. BMSC bone marrow-
derived stromal cell, DAPI 4′,6-diamidino-2-phenylindole. (PNG 558 kb)
Additional file 2: Figure S2. MCP-1 induced significant BMSC migration.
a Immunofluorescent images of representative fields of serum-starved
(24 h) BMSCs migrating in response to a gradient of MCP-1 in a 2D assay.
Permeabilised serum-starved BMSCs immunofluorescently stained with
F-actin (red) and α-tubulin (green) and DNA stained with DAPI (blue). Scale
bar = 30 μm. b BMSC migration in response to the indicated MCP-1
concentrations in a 3D migration assay. Graph represents three separate
independent experiments. Data are presented as mean ± SD. A P value of
less than 0.05 (*) was deemed significant. c Representative 3D migration
assay results from serum-starved BMSCs exposed to the indicated conditions.
2D two-dimensional, 3D three-dimensional, BMSC bone marrow-derived
stromal cell, DAPI 4′,6-diamidino-2-phenylindole, MCP-1 monocyte
chemoattractant protein 1, SD standard deviation. (PNG 571 kb)
Additional file 3: Figure S3. ROCK inhibition affects morphology and
MCP-1-induced migration in mouse BMSCs. Permeabilised serum-starved
BMSCs immunofluorescently stained with F-actin (red) and α-tubulin
(green) and DNA counter-stained with DAPI (blue). a Serum-starved
BMSCs polarise in response to MCP-1; 10 μM Y27632 pre-treatment (24 h)
results in a stellate morphology, with or without MCP-1 treatment. Scale
bar = 10 μm. b Immunofluorescent images of representative fields of
serum-starved (24 h) BMSCs pre-treated with 10 μM Y27632 and exposed
to a gradient of MCP-1 in a 2D assay. Permeabilised serum-starved BMSC
stained with F-actin (red) and α-tubulin (green) and DNA stained with
DAPI (blue). Scale bar = 30 μm. 2D two-dimensional, BMSC bone marrow-
derived stromal cell, DAPI 4′,6-diamidino-2-phenylindole, MCP-1 monocyte
chemoattractant protein 1, ROCK Rho-associated, coiled-coil containing
protein kinase. (PNG 1480 kb)
Additional file 4: Figure S4. Human BMSC chemotactic migration is
unaffected by ROCK inhibition but does display the characteristic
morphology. a Serum-starved human BMSCs polarise in response to
MCP-1; 10 μM Y27632 treatment results in stellate morphology in BMSCs,
independent of MCP-1 treatment. Scale bar = 10 μm. b ROCK inhibition
does not affect human BMSC migration in response to MCP-1.Immunofluorescent images of representative fields of serum-starved
(24 h) BMSCs pre-treated with 10 μM Y27632 and exposed to a
gradient of MCP-1 in a 2D assay. Permeabilised serum-starved BMSCs
stained with F-actin (red) and α-tubulin (green) and DNA stained with
DAPI (blue). Scale bar = 30 μm. c Quantification of b. Graph represents two
separate independent experiments (>100 cells evaluated for each separate
independent experiment). Data are presented as mean ± standard error of
the mean. A P value of less than 0.05 (*) was deemed significant, and a
P <0.001 (***) highly significant. 2D two-dimensional, BMSC bone marrow-
derived stromal cell, DAPI 4′,6-diamidino-2-phenylindole, MCP-1 monocyte
chemoattractant protein 1, ROCK Rho-associated, coiled-coil containing
protein kinase. (PNG 1175 kb)
Additional file 5: Figure S5. CCR2, GPCR βγ subunit and PI3K activity is
required for MCP-1-induced BMSC migration. a-c 3D migration of
serum-starved BMSCs pre-treated with 10 μM RS102895, 10 μM MPS-
Phos, 5 μM LY294002, or 10 μM Y27632 for 24 h prior to exposure to
MCP-1. Representative migration traces shown of three separate
independent experiments; 10 % fetal bovine serum included as a
positive control. 3D three-dimensional, BMSC bone marrow-derived
stromal cell, CCR chemokine (C motif) receptor, GPCR G protein-coupled
receptor, MCP-1 monocyte chemoattractant protein 1, PI3K PI3 kinase.
(PNG 273 kb)
Additional file 6: Figure S6. Inhibitors do not affect BMSC viability or
cytotoxicity or induce apoptosis; 24-h serum starvation (SFM) of BMSCs
alone or in conjunction with 10 μM Y27632, 5 μM LY294002, 10 μM
MPS-Phos, or 0.5 μM Staurosporine. A very low dose of Staurosporine
was included as a positive control for apoptosis. Untreated cells (cultured
in normal media) were included as an untreated control. SFM set = 1.
Graph represents three independent experiments. (Each individual experiment
was performed in triplicate.) Data are presented as mean ± standard error of
the mean. A P value of less than 0.05 (*) was deemed significant, and a P value
of less than 0.01 (**) very significant. BMSC bone marrow-derived stromal cell,
SFM serum-free medium. (PNG 360 kb)
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